Loading data for ACAD — first visit, this takes a few seconds.

알림

ACADIA Pharmaceuticals In... (ACAD)

NasdaqGS: ACAD · 실시간 가격 · USD

30.68

+0.50 (1.66%)

종가 기준: Aug 19, 2026, 2:26 PM

1.66% (1D)

데이터 없음

매수호가	26.34
시가총액	5.29B
매출 (ttm)	1.14B
순이익 (ttm)	380.48M
베타	0.84
EPS (ttm)	2.23
P/E (ttm)	13.76
선행 P/E	34.53
P/B (ttm)	4.04
P/S (ttm)	4.61
Earnings Date	Nov 4, 2026

매도호가	35.06
거래량	448,337
평균 거래량 (20일)	1,617,537
시가	30.66
전일 종가	30.18
일중 범위	30.36 - 30.87
52주 범위	19.69 - 30.87
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

ACAD 소개

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like gr...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 May 27, 2004

직원 수 796

상장 거래소 NasdaqGS

티커 ACAD

웹사이트 https://www.acadia.com

전체 기업 정보

재무 실적

2025년 ACADIA Pharmaceuticals의 매출은 1.07B로, 전년 957.8M 대비 11.87% 증가했습니다. 순이익은 391M로, 72.66% 증가했습니다.

재무제표

어닝 서프라이즈

ACADIA Pharmaceuticals가 Aug 4, 2026에 분기 실적을 발표했습니다:

매출 $307.96M 예상치 하회 $0, 및 16.40% 전년 대비 성장.

EPS 0.18 예상치 상회 0.14, 및 12.50% 전년 대비 성장.

다음 실적 발표

ACADIA Pharmaceuticals Inc.의 실적 발표 예정일은 Nov 4, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

6일 전 · MarketBeat

ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer’s Data

ACADIA Pharmaceuticals (NASDAQ:ACAD) outlined commercial expansion plans for its marketed therapies, DAYBUE and NUPLAZID, while highlighting upcoming clinical data for remlifanserin in Alzheimer’s dis...

1주 전 · Motley Fool

Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript

Revenue hit $308 million with 17% growth, driven by DAYBUE and NUPLAZID demand.

1주 전 · Proactive

Immunic appoints Elena Ridloff to board of directors

Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named Elena Ridloff to its board of directors, the biotechnology company said Monday. Ridloff currently serves as CFO at Sionna Therapeutics. She previously hel...

1주 전 · MT Newswires

Acadia Pharmaceuticals to Gain From Daybue, Nuplazid Growth; RADIANT Data Adds Risk, Morgan Stanley Says

Acadia Pharmaceuticals (ACAD) could benefit from wider Daybue use, steady Nuplazid growth, higher ca

1주 전 · Simply Wall St.

Acadia Pharmaceuticals (ACAD) Stock Gets Fair Value Bump As Analysts Back Daybue Growth

ACADIA Pharmaceuticals has seen its fair value price target adjusted from US$31.80 to US$33.25 per share, reflecting updated assumptions around its business outlook. Recent analyst commentary generall...

2 페이지 중 1